|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIST1H2BC |
Gene summary for HIST1H2BC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIST1H2BC | Gene ID | 8347 |
| Gene name | H2B clustered histone 4 | |
| Gene Alias | H2B.1 | |
| Cytomap | 6p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0002227 | UniProtAcc | B2R4S9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8347 | HIST1H2BC | P49T-E | Human | Esophagus | ESCC | 2.19e-09 | 1.21e+00 | 0.1768 |
| 8347 | HIST1H2BC | P52T-E | Human | Esophagus | ESCC | 3.19e-23 | 4.80e-01 | 0.1555 |
| 8347 | HIST1H2BC | P54T-E | Human | Esophagus | ESCC | 9.26e-30 | 9.27e-01 | 0.0975 |
| 8347 | HIST1H2BC | P56T-E | Human | Esophagus | ESCC | 2.18e-05 | 7.88e-01 | 0.1613 |
| 8347 | HIST1H2BC | P57T-E | Human | Esophagus | ESCC | 7.98e-13 | 5.47e-01 | 0.0926 |
| 8347 | HIST1H2BC | P61T-E | Human | Esophagus | ESCC | 2.38e-25 | 5.69e-01 | 0.099 |
| 8347 | HIST1H2BC | P62T-E | Human | Esophagus | ESCC | 2.46e-39 | 1.09e+00 | 0.1302 |
| 8347 | HIST1H2BC | P65T-E | Human | Esophagus | ESCC | 2.91e-49 | 1.34e+00 | 0.0978 |
| 8347 | HIST1H2BC | P74T-E | Human | Esophagus | ESCC | 7.95e-32 | 1.37e+00 | 0.1479 |
| 8347 | HIST1H2BC | P75T-E | Human | Esophagus | ESCC | 1.82e-62 | 1.54e+00 | 0.1125 |
| 8347 | HIST1H2BC | P76T-E | Human | Esophagus | ESCC | 9.56e-08 | 2.75e-01 | 0.1207 |
| 8347 | HIST1H2BC | P79T-E | Human | Esophagus | ESCC | 7.39e-48 | 1.37e+00 | 0.1154 |
| 8347 | HIST1H2BC | P80T-E | Human | Esophagus | ESCC | 2.74e-11 | 7.00e-01 | 0.155 |
| 8347 | HIST1H2BC | P82T-E | Human | Esophagus | ESCC | 9.88e-07 | 9.99e-01 | 0.1072 |
| 8347 | HIST1H2BC | P83T-E | Human | Esophagus | ESCC | 1.93e-15 | 6.96e-01 | 0.1738 |
| 8347 | HIST1H2BC | P84T-E | Human | Esophagus | ESCC | 8.58e-09 | 1.37e+00 | 0.0933 |
| 8347 | HIST1H2BC | P89T-E | Human | Esophagus | ESCC | 1.17e-12 | 1.50e+00 | 0.1752 |
| 8347 | HIST1H2BC | P91T-E | Human | Esophagus | ESCC | 4.09e-10 | 1.33e+00 | 0.1828 |
| 8347 | HIST1H2BC | P94T-E | Human | Esophagus | ESCC | 4.19e-04 | 6.16e-01 | 0.0879 |
| 8347 | HIST1H2BC | P104T-E | Human | Esophagus | ESCC | 3.07e-05 | 4.58e-01 | 0.0931 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIST1H2BC | SNV | Missense_Mutation | c.214G>C | p.Glu72Gln | p.E72Q | P62807 | protein_coding | deleterious_low_confidence(0.02) | benign(0.172) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
| HIST1H2BC | SNV | Missense_Mutation | c.161N>C | p.Gly54Ala | p.G54A | P62807 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.813) | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.340N>A | p.Glu114Lys | p.E114K | P62807 | protein_coding | tolerated_low_confidence(0.07) | benign(0.031) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.308N>C | p.Leu103Pro | p.L103P | P62807 | protein_coding | deleterious_low_confidence(0.01) | benign(0.43) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| HIST1H2BC | SNV | Missense_Mutation | c.259N>A | p.Arg87Ser | p.R87S | P62807 | protein_coding | deleterious_low_confidence(0.01) | benign(0.14) | TCGA-D8-A1XF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.374C>T | p.Ser125Phe | p.S125F | P62807 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.95) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.133N>C | p.Val45Leu | p.V45L | P62807 | protein_coding | deleterious_low_confidence(0.02) | benign(0.033) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD | |
| HIST1H2BC | SNV | Missense_Mutation | c.214N>C | p.Glu72Gln | p.E72Q | P62807 | protein_coding | deleterious_low_confidence(0.02) | benign(0.172) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| HIST1H2BC | SNV | Missense_Mutation | novel | c.108N>C | p.Glu36Asp | p.E36D | P62807 | protein_coding | deleterious_low_confidence(0.02) | benign(0.047) | TCGA-C5-A1BJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| HIST1H2BC | SNV | Missense_Mutation | c.222N>G | p.Ile74Met | p.I74M | P62807 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.957) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |